Form 4 for STLN Starling Oncology, Inc.
Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-12 · accession 0001799191-24-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-11-18 | 2024-11-12 | STLN | Pacala Mark L | Dir | J - Other | $0.00 | -50.6K | 84.4K | -37% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2024-11-12 | J | D | 20,248 | $0.00 | 114,781 | D | — | — | (F1) Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time. |
| 2 | Common | Common stock | 2024-11-12 | J | D | 30,372 | $0.00 | 84,409 | D | — | — | (F2) Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time. |